share_log

United Health Products Announces Equity Financing Agreement and Provides Corporate Update

United Health Products Announces Equity Financing Agreement and Provides Corporate Update

聯合健康產品宣佈股權融資協議並提供企業最新情況
GlobeNewswire ·  2022/09/06 22:15

Mesquite, NV, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- United Health Products, Inc. (OTCPK: UEEC), (UHP) today announced that it has entered into a common stock purchase agreement to sell up to $10 million of shares to White Lion Capital, LLC (White Lion), a California-based institutional investor. Under the terms of the purchase agreement, UHP will have the right, in its sole discretion, to sell shares to White Lion over a 36-month term. Any common stock sold to White Lion will occur at a purchase price derived from the prevailing market prices of the company's common stock at the time of each sale. The company will control the timing and amount of any shares of common stock sold to White Lion, and White Lion is obligated to make purchases at quantities and prices in accordance with the purchase agreement when requested. UHP's ability to make common stock purchase requests is subject to customary limitations and conditions in the stock purchase agreement, including the registration of the resale of the shares on behalf of White Lion under a registration statement to be filed with the SEC on Form S-3.

內華達州梅斯基特,2022年9月6日(GLOBE NEWSWIRE)——通過NewMediaWire——聯合健康產品公司(OTCPK:UEEC)(UHP)今天宣佈,它已簽訂普通股購買協議,向總部位於加利福尼亞的機構投資者白獅資本有限責任公司(White Lion)出售高達1000萬美元的股票。根據收購協議的條款,UHP將有權自行決定在36個月的期限內向White Lion出售股票。出售給White Lion的任何普通股的購買價格都將根據每次出售時公司普通股的現行市場價格產生。公司將控制向White Lion出售任何普通股的時間和數量,White Lion有義務在收到要求時根據購買協議以數量和價格進行購買。UHP提出普通股購買申請的能力受股票購買協議中的慣例限制和條件的約束,包括根據S-3表格向美國證券交易委員會提交的註冊聲明代表White Lion登記轉售股票。

Separately, the previously announced payments of approximately $1 million to be received by UHP from a former executive of the company have been modified such that the company has received approximately $200,000 and 2,000,000 shares of its common stock are being returned to the company. These shares will be available for reissuance under the above agreement with White Lion.

另外,UHP先前宣佈的從該公司前高管那裏收到的約100萬美元的款項已經修改,使該公司已收到約20萬美元,其2,000,000股普通股將歸還給該公司。根據與White Lion達成的上述協議,這些股票可以重新發行。

The proceeds of any sale of common stock to White Lion will be used for general corporate purposes including the establishment of a manufacturing operation for the company's HemoStyp hemostatic gauze product and the completion of all remaining elements of the FDA Premarket Approval application, and to advance the development of powder and gel formats of the company's patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent.

向White Lion出售普通股的收益將用於一般公司用途,包括建立該公司的HemoStyp止血紗布產品的製造業務和完成美國食品藥品管理局上市前批准申請的所有剩餘內容,以及推進該公司獲得專利的中和氧化再生纖維素(NORC)止血劑的粉末和凝膠格式的開發。

Regarding the company's previously disclosed legal action relating to the audit of its 2017 financial statements, on August 31, 2022 the company and the defendant entered into a settlement agreement under which, among other provisions, UHP will receive a cash payment this month. 

關於該公司先前披露的與其2017年財務報表審計有關的法律行動,公司與被告於2022年8月31日簽訂了一項和解協議,根據該協議,除其他條款外,UHP將在本月獲得現金付款。

Brian Thom, UHP's Chief Executive Officer, commented: "The resolution of this outstanding litigation, combined with the White Lion transaction and the settlement of payments from our former executive, will provide the company with over $1 million in capital to advance its business plan without diluting shareholders."

UHP首席執行官布萊恩·湯姆評論說:“這起未決訴訟的解決,加上白獅交易和我們前高管的款項結算,將爲公司提供超過100萬美元的資本,用於在不稀釋股東的情況下推進其業務計劃。”

Regarding the company's FDA PMA application process, UHP continues to work with its intended manufacturing partner and its regulatory consultant, Regulatory Compliance Associates, to establish production and complete all necessary documentation. UHP is auditing the production facility as well as its documentation and employee training processes, among other elements of the partner's operations. The company's manufacturing equipment will commence production, allowing for the completion of Standard Operating Procedure and Design Control documentation, and the development of the Design Transfer process that will transfer detailed product design information to the manufacturing partner. It is anticipated that the completion of the audit process, establishment and inspection of gauze production, drafting of associated documentation, and testing of product to ensure conformance with previous product specifications will be completed within 60 days. In the interim, the company will continue to provide updates on achievement of milestones in this process.   

關於該公司的FDA PMA申請流程,UHP繼續與其預期的製造合作伙伴及其監管顧問Regular Compliance Associates合作,建立生產並完成所有必要的文件。UHP 正在對生產設施及其文檔和員工培訓流程以及合作伙伴運營的其他內容進行審計。該公司的製造設備將開始生產,從而完成標準操作程序和設計控制文檔,並制定設計轉移流程,將詳細的產品設計信息傳送給製造合作伙伴。預計將在60天內完成審計過程、建立和檢查紗布生產、起草相關文件以及測試產品以確保符合先前產品規格。在此期間,公司將繼續提供有關該過程中實現里程碑的最新情況。

There can be no assurance that the company's PMA application will be approved.

無法保證該公司的PMA申請會獲得批准。

Investor relations:
info@unitedhealthproductsinc.com
475.755.1005

投資者關係:
info@unitedhealthproductsinc.com
475.755.1005

Philippe Niemetz
212 344-6464
p.niemetz@panconsultants.com

菲利普·尼梅茲
212 344-6464
p.niemetz@panconsultants.com

About United Health Products -- United Health Products develops, manufactures and markets HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and consumer markets, and is focused on gaining approval to access the human surgical market. 

關於聯合健康產品— United Health Products 開發、製造和銷售 HemoStyp™,這是一種獲得專利的中和氧化再生纖維素 (NORC) 止血劑。HemoStyp 是一種全天然產品,旨在控制出血。UHP目前爲牙科、獸醫和消費市場提供一套止血產品,並專注於獲得進入人體外科市場的批准。

For more information on UHP visit:  or contact the company at info@unitedhealthproductsinc.com

有關 UHP 的更多信息,請訪問:或通過 info@unitedhealthproductsinc.com 聯繫該公司

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

1995年《私人證券訴訟改革法》下的安全港聲明:本新聞稿可能包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性信息,包括包含 “相信”、“期望”、“預期” 或類似表達方式的聲明。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致公司的實際業績、業績或成就與此類前瞻性陳述所表達或暗示的業績、業績或成就存在重大差異。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論